Novartis (NVS) Excites Incyte (INCY) with Licensing Deal
More News related to INCY
- Incyte to Report 2009 Financial Results and 2010 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18
- Monness, Crespi, Hardt Initiates Coverage on Incyte (INCY) with a Buy
- Incyte Announces Redemption of Its 31/2% Convertible Senior Notes Due 2011 and Its 31/2% Convertible Subordinated Notes Due 2011
- Notable Analyst Rating Changes 1/15: AMD, NRG, K, OMX, PRIM Upgraded; TOL, INCY, AYR, CTCM, PAYX Downgraded
- UBS Downgrades Incyte (INCY) to Neutral
More News related to NVS
- Novartis (NVS) Gains Rights to Develop and Distribute Debio 025; Currently in Phase IIb
- SciClone Pharma (SCLN) and Partner Announce Topline Results for ZADAXIN
- Tasigna Front Line Data Convincing But Not Enough to Displace Gleevec
- Novartis (NVS) Reports Rise In Profits and Names New CEO
- Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
More News related to General News
- Larry Summers Claims Lobbyists Are Slowing Down Financial Reform
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- Stocks Rally On Hopes for a "Big Fat" Greek Bailout
- comScore (SCOR) Reports e-Commerce Spending Up Marginally for Q409 (AMZN, EBAY, BKS, MALL, More...)
- Cadbury (CBY) to Continue Idling of Somerdale Manufacturing Facility, Despite Talks with Kraft (KFT)
Novartis (NYSE: NVS) and Incyte Corp. (NASDAQ: INCY) struck a licensing deal where Novartis will gain access to Incyte's therapies for caner patients and patients with blood-disorders that could be life-threatening.
Novartis agreed to pay Incyte $150 million upfront. The first milestone payment Incyte will receive could be up to $60 million.
Shares of Incyte are trading up 6.61% to $8.23. Novartis is up 0.85% to $55.78.
Related Categories
General NewsMomentum Movers
Stocks Mentioned
+0.32Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
